Harry is an Associate in the health and life sciences team. He has six years’ experience working in public policy from an agency and parliamentary background, focusing on technology, healthcare and European integration.

He has worked with senior politicians and policymakers in Westminster, local government and in EU Institutions on a range of policy issues. He has also spent over two years working in China to advise on trade for both Chinese and Western clients.

At Global Counsel, Harry works with clients in the health and life sciences sector across a range of policy issues, helping to develop innovative and strategic solutions to navigate EU and UK policymaking. Harry also contributes to GC’s output of public analysis and commentary.

Recent examples of his work include:

  • Researching and monitoring health and life sciences policy reforms across Europe to support a pharmaceutical client in shaping their advocacy strategies. 
  • Supporting a client in the technology sector to navigate the UK health and social care ecosystem and engage with relevant policymakers. 
  • Developing content breaking down recent health policy announcements and their implications on industry.

Latest Insights by Harry Bell

Health and Life Sciences icon

Is the UK’s defensiveness towards Chinese tech investment about to spill over into genomics?

Health and Life Sciences

There are signs that it might be. In its Made in China 2025 plan the Chinese government identified health tech, including genomics, as an area of strategic focus. This has been reiterated in the “Healthy China 2030” plan. As is often the case, an emphasis on healthcare from the government has spiked Chinese investment in the domestic industry, but with prices in China…

Read more

View all Insights by Harry Bell